Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

(2011) W. Wu et al.   NEURO-ONCOLOGY

Future of convection-enhanced delivery in the treatment of brain tumors

(2009) Dani S Bidros et al.   Future Oncology

Trial design for evaluation of novel targeted therapies

(2009) John Farley et al.   GYNECOLOGIC ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

TGFβ in Cancer

(2008) Joan Massagué   CELL

Optimising the design of phase II oncology trials: The importance of randomisation

(2008) Mark J. Ratain et al.   EUROPEAN JOURNAL OF CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Endpoints for Assessing Drug Activity in Clinical Trials

(2008) R. Pazdur   ONCOLOGIST